04-30 InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow AQ
04-30 InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-03 InterCure Receives Noncompliance Notice From Nasdaq MT
03-03 InterCure receives Nasdaq notification regarding minimum bid requirement RE
03-03 InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement AQ
02-19 InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million RE
02-19 InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million AQ
12-18 InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court RE
11-03 Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd. CI
11-03 InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd CI
11-03 InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation AQ
25-10-08 InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-10-08 Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow RE
25-10-08 InterCure Ltd H1 2025 revenue NIS 130 million RE
25-10-08 InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow AQ
25-09-19 InterCure to Acquire Cannabis Brand Botanico in Two-Phase Deal MT
25-09-19 Intercure to buy ISHI, gaining access to premium U.S. cannabis tech and brands RE
25-09-19 InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands AQ
25-09-18 InterCure Ltd. agreed to acquire Botanico Ltd. for ILS 25.3 million. CI
25-05-01 InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 PR
25-05-01 InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-12 Intercure Names Announces Board Changes, Effective February 13, 2025 CI
25-02-12 InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak PR
25-02-03 InterCure : Immediate Report PU
25-02-02 InterCure : A meeting to be held on February 3, 2025-Amendment regarding the private placement PU
No results match your criteria
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!